PROFICIENT MISMATCH REPAIR

Clinical trials for PROFICIENT MISMATCH REPAIR explained in plain language.

Never miss a new study

Get alerted when new PROFICIENT MISMATCH REPAIR trials appear

Sign up with your email to follow new studies for PROFICIENT MISMATCH REPAIR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Cholesterol drug may boost immunotherapy in Hard-to-Treat stomach cancer

Disease control Not yet recruiting

This phase 2 trial tests whether adding a cholesterol-lowering drug (Tafolecimab) to standard immunotherapy (Sintilimab) and chemotherapy (SOX) can shrink tumors in 30 people with advanced pMMR/MSS gastric cancer, a type that usually doesn't respond well to immunotherapy alone. T…

Matched conditions: PROFICIENT MISMATCH REPAIR

Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

PROFICIENT MISMATCH REPAIR

Get alerted when new PROFICIENT MISMATCH REPAIR trials appear

Cholesterol drug may boost immunotherapy in Hard-to-Treat stomach cancer